Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bolt Biotherapeutics, Inc.BOLT · Entity 8082 | Chief Operating Officer | September 16, 2026 | September 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bolt Biotherapeutics, Inc.
Report date September 16, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,269 |
Ending reported balance
After 2026-09-18 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-16 · Sale · Disposed 1,417 · Balance 29,028 F1: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2026-09-17 · Sale · Disposed 4,909 · Balance 24,119 F2: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Row 3 · 2026-09-18 · Sale · Disposed 6,850 · Balance 17,269 F3: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F2: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 18, 2026 Filed Sep 21, 2026 22:05 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | SaleCommon Stock | 6,850 | $3.24 | $22,169.34 |
DisclosureSEC source: 0001193125-26-396894 · ownership.xml · nonDerivative · entry 3 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,269 F3 · price: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2026 Filed Sep 21, 2026 22:05 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | SaleCommon Stock | 4,909 | $3.32 | $16,289.53 |
DisclosureSEC source: 0001193125-26-396894 · ownership.xml · nonDerivative · entry 2 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,119 F2 · price: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 16, 2026 Filed Sep 21, 2026 22:05 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | SaleCommon Stock | 1,417 | $3.77 | $5,347.76 |
DisclosureSEC source: 0001193125-26-396894 · ownership.xml · nonDerivative · entry 1 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,028 F1 · price: Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 28, 2026 Filed Feb 4, 2026 21:32 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.71 | $0.00 |
DisclosureSEC source: 0001193125-26-037692 · ownership.xml · derivative · entry 1 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-01-27 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2026. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 17,499 | Not disclosed Strike: $7.02 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 24 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,499 shares Expires 2035-04-30 F17 · price: The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price. F16 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 17,499 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 23 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,499 Underlying: Common Stock · 17,499 shares Expires 2035-04-30 F17 · price: The reporting person agreed to cancellation of an option granted on May 1, 2025, in exchange for a new option having a lower exercise price. F16 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 7,749 | Not disclosed Strike: $14.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 22 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,749 shares Expires 2034-07-22 F15 · price: The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price. F14 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 7,749 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 21 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,749 Underlying: Common Stock · 7,749 shares Expires 2034-07-22 F15 · price: The reporting person agreed to cancellation of an option granted on July 23, 2024, in exchange for a new option having a lower exercise price. F14 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 11,749 | Not disclosed Strike: $25.40 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 20 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,749 shares Expires 2034-03-03 F13 · price: The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price. F12 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 11,749 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 19 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,749 Underlying: Common Stock · 11,749 shares Expires 2034-03-03 F13 · price: The reporting person agreed to cancellation of an option granted on March 4, 2024, in exchange for a new option having a lower exercise price. F12 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 11,399 | Not disclosed Strike: $31.80 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 18 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,399 shares Expires 2033-02-26 F11 · price: The reporting person agreed to cancellation of an option granted on February 27, 2023, in exchange for a new option having a lower exercise price. F10 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 11,399 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 17 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,399 Underlying: Common Stock · 11,399 shares Expires 2033-02-26 F11 · price: The reporting person agreed to cancellation of an option granted on February 27, 2023, in exchange for a new option having a lower exercise price. F10 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 9,499 | Not disclosed Strike: $61.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 16 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,499 shares Expires 2032-02-17 F9 · price: The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,499 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 15 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,499 Underlying: Common Stock · 9,499 shares Expires 2032-02-17 F9 · price: The reporting person agreed to cancellation of an option granted on February 18, 2022, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 4,999 | Not disclosed Strike: $400.00 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 14 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,999 shares Expires 2031-02-03 F8 · price: The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,999 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 13 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,999 Underlying: Common Stock · 4,999 shares Expires 2031-02-03 F8 · price: The reporting person agreed to cancellation of an option granted on February 4, 2021, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 2,142 | Not disclosed Strike: $86.80 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 12 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,142 shares Expires 2030-09-02 F7 · price: The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,142 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 11 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,142 Underlying: Common Stock · 2,142 shares Expires 2030-09-02 F7 · price: The reporting person agreed to cancellation of an option granted on September 3, 2020, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 4,642 | Not disclosed Strike: $54.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 10 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,642 shares Expires 2029-11-12 F6 · price: The reporting person agreed to cancellation of an option granted on November 13, 2019, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 4,642 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 9 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,642 Underlying: Common Stock · 4,642 shares Expires 2029-11-12 F6 · price: The reporting person agreed to cancellation of an option granted on November 13, 2019, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 1,653 | Not disclosed Strike: $44.80 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 8 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,653 shares Expires 2029-01-10 F5 · price: The reporting person agreed to cancellation of an option granted on January 11, 2019, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,653 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 7 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,653 Underlying: Common Stock · 1,653 shares Expires 2029-01-10 F5 · price: The reporting person agreed to cancellation of an option granted on January 11, 2019, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 822 | Not disclosed Strike: $40.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 6 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 822 shares Expires 2028-04-03 F4 · price: The reporting person agreed to cancellation of an option granted on April 4, 2018, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 822 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 5 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 822 Underlying: Common Stock · 822 shares Expires 2028-04-03 F4 · price: The reporting person agreed to cancellation of an option granted on April 4, 2018, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 660 | Not disclosed Strike: $40.60 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 4 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 660 shares Expires 2028-01-17 F3 · price: The reporting person agree to cancellation of an option granted on January 17, 2018, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 660 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 3 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660 Underlying: Common Stock · 660 shares Expires 2028-01-16 F3 · price: The reporting person agree to cancellation of an option granted on January 17, 2018, in exchange for a new option having a lower exercise price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 3,214 | Not disclosed Strike: $42.00 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 2 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,214 shares Expires 2027-01-17 F2 · price: The reporting person agreed to cancellation of an option granted on January 18, 2017, in exchange for a new option having a lower price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 12, 2025 Filed Dec 16, 2025 22:11 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantEmployee Stock Option (Right to Buy) · Derivative | 3,214 | Not disclosed Strike: $5.44 | Not disclosed |
DisclosureSEC source: 0001193125-25-321148 · ownership.xml · derivative · entry 1 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,214 Underlying: Common Stock · 3,214 shares Expires 2027-01-17 F2 · price: The reporting person agreed to cancellation of an option granted on January 18, 2017, in exchange for a new option having a lower price. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 22, 2025 Filed Oct 24, 2025 23:18 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-250333 · ownership.xml · nonDerivative · entry 1 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,918 F1 · date: The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · deemedExecutionDate: The restricted stock units subject to the award will vest in full on September 15, 2026, assuming continued employment through such date. F1 · price: The shares represent restricted stock units that were received as an award, for no consideration. Each restricted stock unit represents the right to receive, at settlement, one share of common stock. Read SEC document |
| May 01, 2025 Filed May 6, 2025 00:41 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0000950170-25-063848 · ownership.xml · derivative · entry 1 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2035-04-30 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2025. Read SEC document |
| July 23, 2024 Filed Jul 24, 2024 21:26 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0000950170-24-086153 · ownership.xml · derivative · entry 1 Yonehiro Grant · CIK 0001428666 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2034-07-22 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following July 15, 2024. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 18:29 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 235,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0000950170-24-026999 · ownership.xml · derivative · entry 1 Yonehiro Grant · CIK 0001428666 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,000 Underlying: Common Stock · 235,000 shares Expires 2034-03-03 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2024. Read SEC document |
| December 06, 2023 Filed Feb 6, 2024 18:10 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 2,500 | $0.78 | $1,955.00 |
DisclosureSEC source: 0001209191-24-002901 · doc5.xml · nonDerivative · entry 1 Yonehiro Grant · CIK 0001428666 · Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,918 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:31 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 228,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001209191-23-013676 · doc4.xml · derivative · entry 1 Yonehiro Grant · CIK 0001428666 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,000 Underlying: Common Stock · 228,000 shares Expires 2033-02-26 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2023. Read SEC document |
| December 06, 2022 Filed Feb 7, 2023 21:54 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 2,500 | $1.18 | $2,953.75 |
DisclosureSEC source: 0001209191-23-007582 · doc5.xml · nonDerivative · entry 2 Yonehiro Grant · CIK 0001428666 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,418 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| June 06, 2022 Filed Feb 7, 2023 21:54 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | PurchaseCommon Stock | 2,500 | $1.64 | $4,101.25 |
DisclosureSEC source: 0001209191-23-007582 · doc5.xml · nonDerivative · entry 1 Yonehiro Grant · CIK 0001428666 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,918 F1 · shares: Shares acquired under the issuer's Employee Stock Purchase Plan. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 02:22 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0000899243-22-007525 · doc4.xml · derivative · entry 1 Yonehiro Grant · CIK 0001428666 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2032-02-17 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/36th of the Shares will vest upon the Reporting Person completing each month of continuous service following January 1, 2022. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 22:09 UTC | Bolt Biotherapeutics, Inc. BOLT · Entity 8082 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008533 · doc4.xml · derivative · entry 1 Yonehiro Grant · CIK 0001428666 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer this option will vest with respect to the shares as follows: 1/48th of the Shares will vest upon the Reporting Person completing each month of continuous service following February 4, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.